Is the price fair?
What VCEL's price assumes
Vericel Corporation trades at 92.9× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
92.9
Trailing P/E · Biotechnology median 31.5 · 2.95× the median: the market pays up for this one
- Price / sales
- 5.59
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.2%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +17%
Growth the price implies · The price pays for +17% free cash flow growth a year for a decade; the business has delivered +43% a year over the last three.
Details›
- Price / book2026-Q1
- 4.59
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $47M
- Market capitalisation
- $2.19B
- 3-year revenue growth
- +20%
- 3-year free cash flow growth
- +43%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.